About NanoTemper TechnologiesAt NanoTemper Technologies, we have one clear goal: a world where every disease is treatable. We are dedicated to building optical tools that take on the toughest molecular characterizations, from drug discovery and scientific research to commercial manufacturing. Our mission is simple — empower scientists to do science that matters and help them push the limits of discovery.

Visit our dedicated Prometheus Panta C webpage to find out more details. For the most up-to-date information, follow NanoTemper Technologies on LinkedIn.

Fully compatible with LIMS, automation platforms, and both low- and high-throughput workflows, Prometheus Panta C supports scalable, data-driven analysis. It delivers critical data in under two hours, accelerating decision-making, reducing risk, and helping bring biologics to market faster.

“This pioneering system enables companies to precisely characterize and identify proteins from preclinical phase through to commercial manufacturing. Our vision is to make every disease treatable – and this is a step toward that future.”

“Prometheus Panta C marks a major milestone in expanding our optical technologies into regulated workflows.” shares Stefan Duhr, CEO of NanoTemper Technologies.

As regulatory pressures grow and timelines shrink, biopharma teams need data they can trust – fast. Controlled by software designed to meet 21 CFR Part 11 regulatory standards, Prometheus Panta C facilitates data integrity through distinct user access groups, while Active Directory integration provides centralized user authentication. Features such as electronic signatures, electronic records, and comprehensive audit trails further strengthen regulatory alignment.

By combining four advanced optical technologies, Prometheus Panta C streamlines developability assessments, process monitoring, and protein identity characterization - all while requiring minimal sample volume.

May 5, 2025 — Munich, Germany — NanoTemper Technologies today introduces Prometheus Panta C, a system built to power biopharma breakthroughs by delivering high-quality protein stability and aggregation data.

NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs from Preclinical to Commercial Manufacturing

NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs from Preclinical to Commercial Manufacturing